Abbott boosts SpectRx holding to 13%:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories is to increase its shareholding in SpectRx, a device maker which is developing a non-invasive glucose monitoring device. Abbott has invested $5.25 million as part of an agreement with Norcross, Georgia-based SpectRx, begun in 1997, increasing its shareholding to 13% from just over 6%. SpectRx is also working with Abbott's rival, Roche Diagnostics, on a screening device based on fluorescence of the eye.